This site uses cookies to store information on your computer. Learn more x

DSM reports Q2 2014 results

Heerlen, NL, 05 Aug 2014 07:15 CEST

  • Q2 2014 EBITDA from continuing operations €293 million
  • Q2 2014 EBITDA includes negative currency effect of about €29 million and a €16 million impact from the fire at a nutrition plant in Switzerland
  • Nutrition delivered improved result versus last two quarters with €222 million EBITDA
  • Performance Materials Q2 EBITDA of €88 million up compared to Q2 2013 and Q1 2014
  • Q2 cash flow from operating activities €126 million
  • Interim dividend of €0.55 per ordinary share
  • Full year 2014 outlook in line with current market expectations

Royal DSM, the Life Sciences and Materials Sciences company, today reported second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014. Nutrition showed improvement compared to the last two quarters. Performance Materials continued its encouraging underlying trend and delivered higher results. Polymer Intermediates was negatively impacted by lower caprolactam margins.

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “DSM delivered improved results versus the first quarter, despite persistent currency headwinds. Performance Materials saw continued positive momentum in a number of end-markets, whereas Polymer Intermediates has seen weaker business conditions for caprolactam.

Market conditions in Nutrition have shown some improvement with good Animal Nutrition performance in Q2, while Human Nutrition still operates in a low growth macro environment for some end-markets due to ongoing pressure on consumer spending. In this environment, the resilience of our integrated value chain is demonstrated by robust margins, highlighting the quality of our Nutrition business. In addition we are undertaking initiatives in the US to reinforce the attractiveness of our dietary supplements end-user categories.

We continue to focus on efficiencies to protect profitability and improve cash flow in the current environment. Despite the weakness in caprolactam, we continue to anticipate to deliver improving financial results in the coming quarters.”